GALDERMA AND NATIONAL BREAST CANCER FOUNDATION COMMEMORATE TEN YEARS OF A BEAUTIFUL PARTNERSHIP
Galderma Group AG Registered Shares GALD
News
EADV 2024 Late Breaking News Sessions: New Galderma Data Demonstrating Nemolizumab’s Long-term Efficacy and Safety in Atopic Dermatitis and Durability in Prurigo Nodularis to Be Shared During Three Oral Presentations
Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024
Galderma Stock Falls After Report That Backers Plan to Sell Shares — Update
GALDERMA LAUNCHES CETAPHIL GENTLE EXFOLIATING LINE WITH GEN-Z IT-GIRL KATIE FANG
Galderma Stock Falls After Report That Backers Plan to Sell Shares
Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis
L'Oreal Buys Stake in Swiss Skincare Company Galderma — 2nd Update
L'Oreal Buys Stake in Swiss Skincare Company Galderma — Update
L'Oreal Buys Stake in Swiss Skincare Company Galderma
Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology
Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe
Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024
PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis – Itch, Skin Lesions and Sleep Disturbance
Galderma Introduces High Potency Cetaphil Serums Designed for Sensitive Skin
Jean Paul Gaultier owner Puig plans $3.25 bln IPO in Spain
United States